294:. Among 36 identified familial carriers of these mutant genes, 4 had no history of IMF, 3 had developed a solitary IMF, 29 had developed multiple tumors (no viscera involvement) or multiple tumors (with viscera involvement) IMF, and 2 had died. Most of these individuals were diagnosed with IMF in their infancy or early childhood. Subsequent studies have found that up to 70% of individuals with IMF and no family history of the disease also carry mutations in one of their two PDGFRB genes in the cells of their tumor tissues. These mutations are
412:
typically due to a tumor's compression of vital organs or tissues (e.g. blood vessels). However, there are uncommon cases of multiple tumors (with viscera involvement) that were not associated with serious symptoms, were observed without treatment, and over time showed spontaneous regressions of all or almost all of their tumors.
221:
spontaneiously. Single tumors located in vital areas (e.g. intracranial tumors) and tumors that do not regress over suitable observation periods are often treated by surgical removal. Multiple tumors (with viscera involvement) and surgically inaccessible life-threatening IMF tumors have been treated with one or a combination of
720:
Individuals with multiple tumors (with viscera involvement) have numerous tumors one or more of which are located in and often injure a vital internal organ and may be life-threatening. Cases in which one of the tumors is in a vital organ and seriously symptomatic have been successfully treated with
1580:
Wenger TL, Bly RA, Wu N, Albert CM, Park J, Shieh J, Chenbhanich J, Heike CL, Adam MP, Chang I, Sun A, Miller DE, Beck AE, Gupta D, Boos MD, Zackai EH, Everman D, Ganapathi S, Wilson M, Christodoulou J, Zarate YA, Curry C, Li D, Guimier A, Amiel J, Hakonarson H, Webster R, Bhoj EJ, Perkins JA, Dahl
550:
gene mutations have been found in 29% of individuals with solitary IMF tumors and 68% of individuals with multiple tumors (with viscera involvement) plus multiple tumors (no visceral involvement) IMF. In about 50% of these cases, these somatic mutations were the same as those found in familial IMF
220:
Treatment of IMF tumors depends upon the tumor numbers, locations, and genetic abnormalities found in each individual and often include more than one therapeutic regimen. Individuals with solitary tumors are usually treated by observation with the expectation that many of these tumors will regress
711:
tests to determine the extent of their disease, particularly with respect to determining if a visceral tumor(s) is present and therefore that the proper diagnosis is multiple tumors (with viscera involvement). The treatment of multiple tumors (no viscera involvement) is similar to that used for
697:
as indicated in the following section on multiple tumors (with visceral involvement). Surgical excision has also be used if the diagnosis of the tumor is in doubt. In rare cases, aggressive IMF tumors have recurred after regressing and required further observation and/or treatment. Overall, the
411:
of brain, and lung. This form of IMF, particularly in cases with tumors involving the gastrointestinal tract, heart, and/or lung, has a far higher morbidity and mortality than the other forms with death occurring in infants during the first weeks to 4 months of life in 30–70% of cases Death is
241:
IMF tumors are usually painless, well-encapsulated, rubbery to hard, and freely movable-to-fixed masses. They may be evident at birth in up to 60% of cases but generally go undetected until they are diagnosed in the first year of life, uncommonly in older infants and young (<10 years/old)
382:
Multiple tumors (no viscera involvement) typically occur as dozens to hundreds of mostly small tumors located in various areas such as the skin, muscles, and frontal eye socket, These tumors do not involve visceral organs, often take a benign course, and may regress spontaneously.
424:
analyses of IMF tumor tissues commonly show repeated patterns of a central zone consisting of spindle-shaped cells lining capillaries and round-to-oval cells arranged around prominent "antler-shaped" vascular spaces all of which are surrounded by a peripheral zone of clustered
692:
strategy is commonly used for these tumors. Visceral solitary IMF tumors that cause significant tissue injury, are located in vital areas, and/or are life-threatening have been treated by surgical excision or, if surgery is deemed inappropriate, are treated with drugs and/or
1152:
Hettmer S, Dachy G, Seitz G, Agaimy A, Duncan C, Jongmans M, Hirsch S, Kventsel I, Kordes U, de
Krijger RR, Metzler M, Michaeli O, Nemes K, Poluha A, Ripperger T, Russo A, Smetsers S, Sparber-Sauer M, Stutz E, Bourdeaut F, Kratz CP, Demoulin JB (October 2021).
1900:
El
Demellawy D, Cundiff CA, Nasr A, Ozolek JA, Elawabdeh N, Caltharp SA, Masoudian P, Sullivan KJ, de Nanassy J, Shehata BM (2016). "Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement".
706:
Multiple tumors (no viscera involvement) also may regress spontaneously and carry a good to excellent prognosis even when they invade local tissues. However, neonates presenting with multiple IMF tumors should undergo a through examination including
170:
multiple tumors (with viscera involvement) (also called generalized myofibromatosis) which rarely regress spontaneously and consist of numerous IMF lesions in non-visceral tissues plus one or more visceral tumors that may be life-threatening.
2096:
1430:
Proust S, Benchimol G, Fraitag S, Starck J, Giacobbi V, Pierron G, Bodemer C, Orbach D (January 2021). "Major response to imatinib and chemotherapy in a newborn patient prenatally diagnosed with generalized infantile myofibromatosis".
721:
surgical resection. Cases where surgical resection of a single symptomatic tumor is not a good option and cases with multiple visceral tumors are treated by non-surgical methods. These tumors typically respond to conventional systemic
679:
There are no controlled studies to define the optimal treatment(s) for IMF. The following give the currently widely used and recommended treatments along with the result of these treatments for the three categories of the IMF tumors.
530:) mutation in the carrier family was p. Leu1519Pro. The p.Arg561Cys, p.Pro560Leu, p.Arg561Ser, and p. Lys567Glu mutations are regarded as contributing to the development and/or progression of IMF while the p.Pro660Thr
391:
Multiple tumors (with viscera involvement) typically occur as dozens to hundreds of tumors located in the same sites as multiple tumors (no viscera involvement) but also occur in one or more visceral organs such as those in the
262:
masses. Most of these tumors are <1 cm in diameter but can be much larger, e.g. 5.2 cm in diameter. At least 9 IMF cases described in the
English literature were diagnosed in fetuses based on the findings of fetal
309:
genes has been reported to occur in a single family with autosomal dominant inheritance of IMF: 9 of this family's members had IMF plus the mutation while 7 of its members did not have IMF or the mutation. Since the mutated
618:
blocks the activity of the p.Arg561Cys and p.Asn666Lys mutants as well as the p.Arg561Cyt plus Asp666Lys and p.Trp566Arg plus AspN666Lys double mutants but not the p.Asp850Val mutant. Two other tyrosine kinase inhibitors,
769:, has also been used as a single-drug treatment in at least one of these cases. Multiple tumors (with viscera involvement) have also been treated with surgical resection in combination with these drugs and/or with
1215:
Pekar-Zlotin M, Levinsohn-Tavor O, Livneh A, Sher O, Melcer Y, Maymon R (October 2019). "Gynecology and
Oncology Fetal Myofibromatosis: A Challenge for Prenatal Diagnosis Mini Review of the English Literature".
788:
the tyrosine kinase inhibitor should be selected based on the PDGFRB oncoprotein's sensitivity to it (e.g. dasatinib or ponatinib should be used to treat patients with the imatinib-resistant p.Asp850Val
614:, i.e. a normal gene that when mutated could form a cancer-causing oncoprotein. Studies show that the PDGFRB mutant proteins in IMF are constitutively overactive and that the tyrosine kinase inhibitor
271:. IMF tumors in the viscera or deep tissues may present with serious or life-threatening signs and symptoms of organ and/or deep tissue damage due to these tumors space-filling and pressuring effects.
1985:
Laskin WB, Miettinen M, Fetsch JF (January 2009). "Infantile digital fibroma/fibromatosis: a clinicopathologic and immunohistochemical study of 69 tumors from 57 patients with long-term follow-up".
805:
the inhibitors precise dosages for use in newborns and infants are not well-defined, have serious side-affects, and therefore should only be considered for refractory, life-threatening IMF tumors.
663:, a tumor that develops primarily in the fingers and toes, had been regarded as a type of IMF. However its tumors have a distinctly different clinical presentation and histopathology than IMF. The
1336:
Arts FA, Sciot R, Brichard B, Renard M, de Rocca Serra A, Dachy G, Noël LA, Velghe AI, Galant C, Debiec-Rychter M, Van Damme A, Vikkula M, Helaers R, Limaye N, Poirel HA, Demoulin JB (May 2017).
873:
Manisterski M, Benish M, Levin D, Shiran SI, Sher O, Gortzak Y, Elhasid R (February 2021). "Diverse presentation and tailored treatment of infantile myofibromatosis: A single-center experience".
571:) plus AspN666Lys in another case. Three cases had more complex mutations involving multiple gene sites with two of them having the p.Asn666Lys mutation gene in combination with other mutations.
586:
gene product, the PDGFβ receptor, is normally highly expressed in fibroblasts and other cells of mesenchymal origin including vascular smooth muscle cells. When activated, the PDGFβ receptor's
725:
with reductions in their sizes; these responses are usually observed only after several weeks of therapy. Chemotherapy regimes that have successfully treated these cases include low dosage:
1082:
Sparber-Sauer M, Vokuhl C, Seitz G, Sorg B, Tobias M, von Kalle T, Münter M, Bielack SS, Ladenstein R, Ljungman G, Niggli F, Frühwald M, Loff S, Klingebiel T, Koscielniak E (October 2021).
2182:
1084:"Infantile myofibromatosis: Excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry"
2717:
643:, and tumorous lesions particular in cases which involve multiple tumors. However, the presence of two zone histopathology, family history of disease, and presence of the above cited
338:
Solitary IMF tumors represent 50 to 74% of all IMF cases. These tumors commonly present with a mass that infiltrates the surrounding tissue in the head and neck areas (e.g. in the
1634:
Hassan M, Butler E, Wilson R, Roy A, Zheng Y, Liem P, Rakheja D, Pavlick D, Young LL, Rosenzweig M, Erlich R, Ali SM, Leavey PJ, Parsons DW, Skapek SX, Laetsch TW (October 2019).
950:
2737:
302:
genes produce highly overactive platelet-derived growth factor receptor beta (i.e. PDGFβ receptor) proteins that contribute to the development and/or progression of IMF.
298:(i.e. non-inherited mutations developing only after conception) that are identical or similar to those seen in familial cases. The familial and non-familial mutated
651:
have been suggested to be the same disease because of their very similar histopathology. However, mesoblastic nephroma tumor cells, unlike IMF tumor cells, express
1476:"Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation"
627:, do inhibit the p.Asp850Val mutant's tyrosine kinase activity. Limited initial studies suggest that these inhibitors are useful in treating severe cases of IMF.
2175:
784:, have successful treated several cases and chemotherapy plus imatinib have successfully treated a few cases of life-threatening IMF. Studies suggest that:
174:
A minority of infantile myofibromatosis tumors present in individuals with a strong family history of the disease. These familial cases are associated with
314:
gene in this family produces an overactive neurogenic locus notch homolog protein 3 product that in cell culture studies increases the expression of the
1786:
Iwafuchi H, Tsuzuki T, Ito R, Miyake H, Okita H, Hamazaki M (August 2015). "Generalized infantile myofibromatosis with a monophasic primitive pattern".
2848:
2168:
162:
multiple tumors (no viscera involvement) which consists of numerous (i.e. dozens to >100) IMF lesions most of which are located in the skin and
668:
1688:"The infantile myofibromatosis NOTCH3 L1519P mutation leads to hyperactivated ligand-independent Notch signaling and increased PDGFRB expression"
141:, carry guarded to poor prognoses and can be life-threatening, particularly in newborns and young infants. The condition was first described by
688:
Solitary IMF tumors typically grow slowly, produce few or no symptoms, and often regress spontaneously within 18 to 24 months of diagnosis. A
551:
with the remaining cases having mutations in other sites of the gene. These other somatic mutation sites included 2 cases of p.Asp850Val (Asp=
928:
242:
children, or rarely in older children and adults (one individual was diagnosed with IMF at 85 years of age). The tumors may be flesh-colored
2538:
2385:
1686:
Wu D, Wang S, Oliveira DV, Del Gaudio F, Vanlandewijck M, Lebouvier T, Betsholtz C, Zhao J, Jin S, Lendahl U, Karlström H (January 2021).
2221:
2108:
610:
which in turn promote their parent cells to grow, proliferate, and survive for abnormally prolonged times. The PDGFβ receptor gene is a
326:
mutant genes, i.e. by increasing the number and therefore overall activity of the PDGFβ receptor. Further studies are needed to define
274:
Some individuals with IMF present with a family history of IMF tumors. To date (2021), 20 families have been reported to carry various
797:
imatinib should be the initial choice and dasatinib or ponatinib be used for cases failing to respond to imatinib in cases where the
2298:
2789:
1581:
JP, Dobyns WB (July 2020). "Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy".
2557:
2266:
824:
635:
Based on their clinical presentation and gross appearance IMF tumors can be confused with a wide range of benign and malignant
2333:
2318:
2313:
660:
2431:
2338:
595:
2732:
2722:
2443:
1384:
Zhao G, Zhu M, Qin C, Liu X, Zhao X (November 2020). "Infantile
Myofibromatosis: 32 Patients and Review of Literature".
819:
2380:
429:-like cells. The relative proportions of the two zones can vary within different areas of a tumor and between tumors.
44:
Myofibromas, Multicentric fibromatosis, Congenital generalized fibromatosis, and
Congenital multicentric fibromatosis
2660:
2236:
944:
Beck, Jill C.; Devaney, Kenneth O.; Weatherly, Robert A.; Koopmann, Charles F.; Lesperance, Marci M. (1999-01-01).
498:
of the genes product protein, the PDGFβ receptor. Four of the remaining families carried either a p.Pro560Leu (Pro=
268:
1857:
Soundararajan M, Kannan S (December 2018). "Fibroblasts and mesenchymal stem cells: Two sides of the same coin?".
1155:"Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group"
374:, lung, or heart. Solitary IMF tumors often (i.e. 25 to 61% of cases in different studies) regress spontaneously.
2784:
2672:
2453:
664:
158:
solitary IMF tumors (also called myofibromas) which often regress spontaneously and rarely cause serious issues;
201:
gene mutations. Regardless of these genetic variations, all IMF tumors consist of bland-appearing, benign (i.e.
125:
found in 1 in 150,000 to 1 in 400,000 live births. It is nonetheless the most common tumor derived from fibrous
2323:
2119:
538:
p. Leu1519Pro gene mutation require further study to determine more clearly their clinical significances.
2769:
366:
area, lower back, or soft tissue/bone in the lower leg; and also less commonly in visceral organs such as the
1636:"Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib"
2751:
2509:
2353:
2293:
2245:
397:
2853:
2587:
2438:
2395:
2390:
393:
2148:
76:
Solitary tumor, Multiple tumors (no viscera involvement), and
Multiple tumors (with viscera involvement)
1268:"Primary Resection and Immediate Autologous Reconstruction of Fronto-orbital Infantile Myofibromatoses"
2774:
2619:
2343:
2271:
1737:"Fibroblastic and myofibroblastic tumors of children: new genetic entities and new ancillary testing"
648:
287:
163:
197:
gene mutations in their tumor cells; these mutations are similar to those occurring in the familial
2764:
2690:
2572:
2372:
2348:
2308:
2303:
2216:
430:
347:
214:
1938:"Congenital mesoblastic nephroma: Clinical analysis of eight cases and a review of the literature"
1830:"PDGFRB platelet derived growth factor receptor beta [Homo sapiens (Human)] - Gene - NCBI"
2727:
2702:
2665:
2562:
2531:
2495:
2328:
2010:
1882:
1811:
1616:
1562:
1456:
1409:
1241:
1111:
898:
255:
142:
567:), and concurrent double mutations p.Arg561Cyt plus Asp666Lys in one case and p.Trp566Arg (Trp=
2827:
2799:
2707:
2567:
2358:
2191:
2059:
2002:
1967:
1918:
1874:
1803:
1768:
1717:
1665:
1608:
1554:
1505:
1448:
1401:
1359:
1297:
1233:
1184:
1103:
1057:
977:
969:
924:
890:
770:
766:
694:
640:
275:
247:
226:
126:
49:
2160:
254:(i.e. flat-topped papules that are equal to or greater than 10 mm in largest diameter);
2656:
2552:
2490:
2426:
2049:
2041:
1994:
1957:
1949:
1910:
1866:
1795:
1758:
1748:
1707:
1699:
1655:
1647:
1598:
1590:
1544:
1536:
1495:
1487:
1440:
1393:
1349:
1287:
1279:
1225:
1174:
1166:
1095:
1047:
1037:
959:
882:
758:
689:
667:(2020) redefined infantile digital fibromatosis as a benign tumor in the category of benign
471:
408:
295:
647:
gene mutations are almost always definitive indicators of IMF. IMF and the classic form of
2643:
2471:
708:
603:
587:
421:
343:
213:, the most common cell type in connective tissue, with a variable set of features seen in
138:
2779:
1083:
458:
Twenty families with inherited IMF have been shown to have mutations in one of their two
330:
gene mutation's frequency of occurrence in, and contribution to the development of, IMF.
233:
gene mutations, drugs directed specifically against this mutated gene's protein product.
166:
but not visceral organs, may regress spontaneously, and rarely cause serious issues; and
1549:
1524:
2804:
2794:
2712:
2697:
2632:
2543:
2481:
2461:
2054:
2029:
1962:
1937:
1763:
1736:
1712:
1687:
1660:
1635:
1500:
1475:
1292:
1267:
1179:
1154:
1052:
1025:
742:
611:
591:
251:
206:
322:
mutation may promote the development and/or progression of IMF in a manner similar to
2842:
1620:
1566:
1460:
1413:
1245:
1115:
1026:"What to Look Out for in a Newborn with Multiple Papulonodular Skin Lesions at Birth"
902:
780:-associated IMF cases. Imatinib or imatinib plus a second tyrosine kinase inhibitor,
750:
659:
proteins and therefore likely have a very different cellular origin than IMF tumors.
527:
426:
405:
355:
339:
193:. However, most IMF cases have no family history of the disease but nonetheless have
2014:
1886:
1815:
1042:
100:
Guarded in multiple tumors (with visceral involvement); otherwise, good to excellent
2822:
2466:
2368:
2285:
2258:
2226:
1753:
746:
738:
730:
722:
656:
599:
475:
222:
147:
2124:
1998:
1914:
1491:
1397:
1283:
1229:
482:
gene mutations, 15 carried a p.Arg561Cys mutation. This mutation substitutes the
2814:
2652:
2526:
2521:
2421:
2195:
814:
734:
726:
351:
264:
134:
54:
1540:
1170:
17:
2759:
2608:
964:
945:
754:
568:
560:
495:
483:
401:
291:
210:
202:
58:
973:
2685:
2628:
2577:
781:
652:
624:
620:
552:
519:
515:
467:
283:
175:
95:
2063:
2045:
2030:"The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives"
2006:
1971:
1922:
1878:
1807:
1772:
1721:
1669:
1612:
1558:
1509:
1452:
1405:
1363:
1301:
1237:
1188:
1107:
1061:
894:
981:
2198:
2143:
1953:
1843:
1829:
1594:
1354:
1338:"PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis"
1337:
762:
615:
487:
438:
367:
259:
137:
to distant tissues although when occurring in the viscera, i.e. internal
2088:
1651:
1603:
2281:
2254:
2202:
1703:
503:
499:
491:
359:
243:
1870:
1844:"NOTCH3 notch receptor 3 [Homo sapiens (Human)] - Gene - NCBI"
1799:
1444:
1099:
886:
2517:
2417:
2409:
2100:
1523:
Guérit E, Arts F, Dachy G, Boulouadnine B, Demoulin JB (April 2021).
636:
564:
556:
511:
507:
442:
371:
363:
186:
180:
145:
as congenital generalized fibromatosis – in which he coined the word
130:
86:
698:
prognosis in almost all cases of solitary IMF is good to excellent.
129:
that occurs primarily in infants and young children. IMF tumors are
1474:
Antonescu CR, Sung YS, Zhang L, Agaram NP, Fletcher CD (May 2017).
286:(i.e. the mutant gene's product is overactive) and inherited in an
2604:
434:
122:
919:
Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007).
433:
analyses indicate that the spindle-shaped cells strongly express
2113:
607:
190:
2164:
1266:
Lavie JL, Rogers CL, Stalder MW, St
Hilaire H (January 2021).
776:
Recently, tyrosine kinase inhibitors have been used to treat
494:
at the 561st amino acid position as numbered starting at the
209:, i.e. cells that blend a variable set of features seen in
526:
gene (located in band 13.12 on the short (or "p") arm of
2718:
Multiple cutaneous and uterine leiomyomatosis syndrome
27:
Rare tumor in infants originating in connective tissue
2078:
2813:
2750:
2641:
2617:
2595:
2586:
2508:
2480:
2452:
2408:
2367:
2280:
2253:
2244:
2235:
2209:
2134:
2082:
104:
94:
84:Familial and non-familial somatic mutations in the
80:
72:
64:
48:
40:
35:
951:Archives of Otolaryngology–Head & Neck Surgery
1936:Wang ZP, Li K, Dong KR, Xiao XM, Zheng S (2014).
2028:Sbaraglia M, Bellan E, Dei Tos AP (April 2021).
946:"Pediatric Myofibromatosis of the Head and Neck"
1681:
1679:
1425:
1423:
1379:
1377:
1375:
1373:
1331:
1272:Plastic and Reconstructive Surgery. Global Open
1147:
1145:
1019:
1017:
1015:
1013:
1011:
868:
866:
864:
862:
860:
278:(i.e. inherited) mutations in one of their two
1329:
1327:
1325:
1323:
1321:
1319:
1317:
1315:
1313:
1311:
1261:
1259:
1257:
1255:
1210:
1208:
1206:
1204:
1202:
1200:
1198:
1143:
1141:
1139:
1137:
1135:
1133:
1131:
1129:
1127:
1125:
1077:
1075:
1073:
1071:
1009:
1007:
1005:
1003:
1001:
999:
997:
995:
993:
991:
858:
856:
854:
852:
850:
848:
846:
844:
842:
840:
2176:
154:IMF tumors occur in three clinical patterns:
8:
1583:American Journal of Medical Genetics. Part A
358:); less commonly in other sites such as the
1525:"PDGF receptor mutations in human diseases"
2592:
2250:
2241:
2183:
2169:
2161:
2079:
1987:The American Journal of Surgical Pathology
1480:The American Journal of Surgical Pathology
914:
912:
716:Multiple tumors (with viscera involvement)
387:Multiple tumors (with viscera involvement)
32:
2053:
1961:
1762:
1752:
1711:
1659:
1640:Cold Spring Harbor Molecular Case Studies
1602:
1548:
1499:
1353:
1291:
1178:
1051:
1041:
963:
757:; and vincristine plus dactinomycin plus
534:gene mutation and the p. Leu1519Pro
318:gene's product, the PDGFβ receptor, this
1386:Journal of Pediatric Hematology/Oncology
801:gene mutation has not been defined; and
702:Multiple tumors (no viscera involvement)
378:Multiple tumors (no viscera involvement)
836:
669:fibroblastic and myofibroblastic tumors
1218:Obstetrical & Gynecological Survey
7:
1529:Cellular and Molecular Life Sciences
1024:Fraitag S, Boccara O (August 2021).
773:alone or combined with these drugs.
2222:Desmoplastic small-round-cell tumor
282:genes. All of these mutations were
671:and therefore different than IMF.
258:, calcified masses; or ulcerated,
25:
2299:Aggressive infantile fibromatosis
2790:Clear-cell sarcoma of the kidney
522:) mutation in this protein. The
2849:Dermal and subcutaneous growths
2558:Intradermal spindle cell lipoma
2267:Dermatofibrosarcoma protuberans
1692:Disease Models & Mechanisms
1043:10.3390/dermatopathology8030043
2386:Malignant fibrous histiocytoma
2334:Infantile digital fibromatosis
2319:Familial myxovascular fibromas
2314:Diffuse infantile fibromatosis
1859:Journal of Cellular Physiology
1754:10.12688/f1000research.16236.1
661:Infantile digital fibromatosis
559:), 2 case of p.Asn666Lys (Asn=
133:in the sense that they do not
1:
2432:Superficial acral fibromyxoma
2339:Juvenile hyaline fibromatosis
596:phosphatidylinositol-3 kinase
305:A mutation in one of the two
2733:Solitary cutaneous leiomyoma
2723:Multiple cutaneous leiomyoma
2444:Ossifying fibromyxoid tumour
1999:10.1097/PAS.0b013e3181788533
1915:10.1016/j.pathol.2015.11.007
1492:10.1097/PAS.0000000000000811
1433:Pediatric Blood & Cancer
1398:10.1097/MPH.0000000000001603
1284:10.1097/GOX.0000000000003261
1230:10.1097/OGX.0000000000000717
1088:Pediatric Blood & Cancer
875:Pediatric Blood & Cancer
820:List of cutaneous conditions
2381:Benign fibrous histiocytoma
229:or, in tumors with certain
2870:
2661:Embryonal rhabdomyosarcoma
2237:Connective tissue neoplasm
1541:10.1007/s00018-020-03753-y
1171:10.1007/s10689-020-00204-2
510:); p. Lys567Glu (Lys=
478:. Of the 20 families with
284:gain of function mutations
269:magnetic resonance imaging
2785:Malignant rhabdoid tumour
2752:Complex mixed and stromal
2681:
2673:Alveolar rhabdomyosarcoma
965:10.1001/archotol.125.1.39
921:Dermatology: 2-Volume Set
753:plus the glucocorticoid,
665:World Health Organization
400:and/or the heart, liver,
115:Infantile myofibromatosis
36:Infantile myofibromatosis
2324:Fibroma of tendon sheath
1342:Human Molecular Genetics
68:Infancy, early childhood
2354:Oral submucous fibrosis
2294:Aggressive fibromatosis
2210:Not otherwise specified
1788:Pathology International
741:; vinblastine plus the
675:Treatment and prognosis
518:); or p.Pro660Thr (Thr=
398:upper respiratory tract
2396:Solitary fibrous tumor
2391:Atypical fibroxanthoma
2046:10.32074/1591-951X-213
441:, and, less commonly,
394:gastrointestinal tract
2770:Mixed Müllerian tumor
712:solitary IMF tumors.
490:, for the amino acid
292:incomplete penetrance
2775:Mesoblastic nephroma
2344:Plantar fibromatosis
2272:Desmoplastic fibroma
1954:10.3892/ol.2014.2489
1595:10.1002/ajmg.a.61615
923:. St. Louis: Mosby.
825:mesoblastic nephroma
649:mesoblastic nephroma
506:); p.Arg561Ser (Ser=
354:, behind an ear, or
164:subcutaneous tissues
2765:Pleomorphic adenoma
2573:Spindle cell lipoma
2373:histiocytic sarcoma
2349:Pleomorphic fibroma
2309:Collagenous fibroma
2304:Aponeurotic fibroma
2217:Soft-tissue sarcoma
1652:10.1101/mcs.a004440
749:; vincristine plus
684:Solitary IMF tumors
466:gene is located in
435:smooth muscle actin
431:Immunohistochemical
348:infratemporal fossa
334:Solitary IMF tumors
215:smooth muscle cells
2728:Neural fibrolipoma
2703:Angiolipoleiomyoma
2666:Sarcoma botryoides
2563:Pleomorphic lipoma
2532:Myxoid liposarcoma
2496:Clear-cell sarcoma
2329:Fibromatosis colli
2135:External resources
1735:Parham DM (2018).
1704:10.1242/dmm.046300
1355:10.1093/hmg/ddx081
449:Gene abnormalities
288:autosomal dominant
143:Arthur Purdy Stout
2836:
2835:
2828:Adenomatoid tumor
2800:Pancreatoblastoma
2746:
2745:
2708:Genital leiomyoma
2568:Lipoblastomatosis
2504:
2503:
2404:
2403:
2359:Pachydermodactyly
2158:
2157:
1871:10.1002/jcp.26860
1865:(12): 9099–9109.
1800:10.1111/pin.12312
1445:10.1002/pbc.28576
1348:(10): 1801–1810.
1100:10.1002/pbc.29403
930:978-1-4160-2999-1
887:10.1002/pbc.28769
793:gene mutation.);
771:radiation therapy
695:radiation therapy
594:proteins such as
472:long (or "q") arm
296:somatic mutations
227:radiation therapy
127:connective tissue
112:
111:
30:Medical condition
16:(Redirected from
2861:
2657:rhabdomyosarcoma
2646:
2622:
2598:
2593:
2553:Chondroid lipoma
2491:Synovial sarcoma
2427:Cutaneous myxoma
2251:
2242:
2185:
2178:
2171:
2162:
2080:
2068:
2067:
2057:
2025:
2019:
2018:
1982:
1976:
1975:
1965:
1948:(5): 2007–2011.
1942:Oncology Letters
1933:
1927:
1926:
1897:
1891:
1890:
1854:
1848:
1847:
1840:
1834:
1833:
1826:
1820:
1819:
1783:
1777:
1776:
1766:
1756:
1732:
1726:
1725:
1715:
1683:
1674:
1673:
1663:
1631:
1625:
1624:
1606:
1589:(7): 1576–1591.
1577:
1571:
1570:
1552:
1535:(8): 3867–3881.
1520:
1514:
1513:
1503:
1471:
1465:
1464:
1427:
1418:
1417:
1381:
1368:
1367:
1357:
1333:
1306:
1305:
1295:
1263:
1250:
1249:
1212:
1193:
1192:
1182:
1149:
1120:
1119:
1079:
1066:
1065:
1055:
1045:
1030:Dermatopathology
1021:
986:
985:
967:
941:
935:
934:
916:
907:
906:
870:
767:interferon alpha
759:cyclophosphamide
690:watchful waiting
542:Non-familial IMF
33:
21:
2869:
2868:
2864:
2863:
2862:
2860:
2859:
2858:
2839:
2838:
2837:
2832:
2809:
2742:
2677:
2644:Skeletal muscle
2642:
2637:
2618:
2613:
2596:
2582:
2500:
2476:
2472:Phyllodes tumor
2454:Fibroepithelial
2448:
2400:
2363:
2276:
2231:
2205:
2189:
2159:
2154:
2153:
2130:
2129:
2091:
2077:
2072:
2071:
2027:
2026:
2022:
1984:
1983:
1979:
1935:
1934:
1930:
1899:
1898:
1894:
1856:
1855:
1851:
1842:
1841:
1837:
1828:
1827:
1823:
1785:
1784:
1780:
1734:
1733:
1729:
1685:
1684:
1677:
1633:
1632:
1628:
1579:
1578:
1574:
1522:
1521:
1517:
1473:
1472:
1468:
1429:
1428:
1421:
1383:
1382:
1371:
1335:
1334:
1309:
1265:
1264:
1253:
1224:(10): 607–610.
1214:
1213:
1196:
1159:Familial Cancer
1151:
1150:
1123:
1081:
1080:
1069:
1023:
1022:
989:
943:
942:
938:
931:
918:
917:
910:
872:
871:
838:
833:
811:
718:
709:medical imaging
704:
686:
677:
633:
604:phospholipase C
588:tyrosine kinase
580:
544:
456:
451:
422:histopathologic
418:
389:
380:
344:maxillary sinus
336:
239:
31:
28:
23:
22:
18:Myofibromatosis
15:
12:
11:
5:
2867:
2865:
2857:
2856:
2851:
2841:
2840:
2834:
2833:
2831:
2830:
2825:
2819:
2817:
2811:
2810:
2808:
2807:
2805:Carcinosarcoma
2802:
2797:
2795:Hepatoblastoma
2792:
2787:
2782:
2777:
2772:
2767:
2762:
2756:
2754:
2748:
2747:
2744:
2743:
2741:
2740:
2735:
2730:
2725:
2720:
2715:
2713:Leiomyosarcoma
2710:
2705:
2700:
2698:Angioleiomyoma
2695:
2694:
2693:
2682:
2679:
2678:
2676:
2675:
2670:
2669:
2668:
2649:
2647:
2639:
2638:
2636:
2635:
2633:leiomyosarcoma
2625:
2623:
2615:
2614:
2612:
2611:
2601:
2599:
2590:
2584:
2583:
2581:
2580:
2575:
2570:
2565:
2560:
2555:
2549:
2548:
2547:
2546:
2544:Angiomyolipoma
2536:
2535:
2534:
2529:
2514:
2512:
2506:
2505:
2502:
2501:
2499:
2498:
2493:
2487:
2485:
2478:
2477:
2475:
2474:
2469:
2464:
2462:Brenner tumour
2458:
2456:
2450:
2449:
2447:
2446:
2441:
2436:
2435:
2434:
2429:
2414:
2412:
2406:
2405:
2402:
2401:
2399:
2398:
2393:
2388:
2383:
2377:
2375:
2365:
2364:
2362:
2361:
2356:
2351:
2346:
2341:
2336:
2331:
2326:
2321:
2316:
2311:
2306:
2301:
2296:
2290:
2288:
2278:
2277:
2275:
2274:
2269:
2263:
2261:
2248:
2239:
2233:
2232:
2230:
2229:
2224:
2219:
2213:
2211:
2207:
2206:
2190:
2188:
2187:
2180:
2173:
2165:
2156:
2155:
2152:
2151:
2139:
2138:
2136:
2132:
2131:
2128:
2127:
2116:
2105:
2092:
2087:
2086:
2084:
2083:Classification
2076:
2075:External links
2073:
2070:
2069:
2020:
1977:
1928:
1892:
1849:
1835:
1821:
1778:
1727:
1675:
1646:(5): a004440.
1626:
1572:
1515:
1486:(5): 677–684.
1466:
1419:
1392:(8): 495–498.
1369:
1307:
1251:
1194:
1165:(4): 327–336.
1121:
1067:
1036:(3): 390–417.
987:
936:
929:
908:
835:
834:
832:
829:
828:
827:
822:
817:
810:
807:
743:glucocorticoid
717:
714:
703:
700:
685:
682:
676:
673:
632:
629:
612:proto-oncogene
592:cell signaling
579:
573:
543:
540:
455:
452:
450:
447:
417:
414:
388:
385:
379:
376:
335:
332:
238:
235:
207:myofibroblasts
178:in either the
110:
109:
106:
102:
101:
98:
92:
91:
82:
78:
77:
74:
70:
69:
66:
62:
61:
52:
46:
45:
42:
38:
37:
29:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
2866:
2855:
2854:Rare diseases
2852:
2850:
2847:
2846:
2844:
2829:
2826:
2824:
2821:
2820:
2818:
2816:
2812:
2806:
2803:
2801:
2798:
2796:
2793:
2791:
2788:
2786:
2783:
2781:
2778:
2776:
2773:
2771:
2768:
2766:
2763:
2761:
2758:
2757:
2755:
2753:
2749:
2739:
2736:
2734:
2731:
2729:
2726:
2724:
2721:
2719:
2716:
2714:
2711:
2709:
2706:
2704:
2701:
2699:
2696:
2692:
2689:
2688:
2687:
2684:
2683:
2680:
2674:
2671:
2667:
2664:
2663:
2662:
2658:
2654:
2651:
2650:
2648:
2645:
2640:
2634:
2630:
2627:
2626:
2624:
2621:
2620:Smooth muscle
2616:
2610:
2606:
2603:
2602:
2600:
2594:
2591:
2589:
2585:
2579:
2576:
2574:
2571:
2569:
2566:
2564:
2561:
2559:
2556:
2554:
2551:
2550:
2545:
2542:
2541:
2540:
2537:
2533:
2530:
2528:
2525:
2524:
2523:
2519:
2516:
2515:
2513:
2511:
2507:
2497:
2494:
2492:
2489:
2488:
2486:
2483:
2479:
2473:
2470:
2468:
2465:
2463:
2460:
2459:
2457:
2455:
2451:
2445:
2442:
2440:
2437:
2433:
2430:
2428:
2425:
2424:
2423:
2419:
2416:
2415:
2413:
2411:
2407:
2397:
2394:
2392:
2389:
2387:
2384:
2382:
2379:
2378:
2376:
2374:
2370:
2366:
2360:
2357:
2355:
2352:
2350:
2347:
2345:
2342:
2340:
2337:
2335:
2332:
2330:
2327:
2325:
2322:
2320:
2317:
2315:
2312:
2310:
2307:
2305:
2302:
2300:
2297:
2295:
2292:
2291:
2289:
2287:
2283:
2279:
2273:
2270:
2268:
2265:
2264:
2262:
2260:
2256:
2252:
2249:
2247:
2243:
2240:
2238:
2234:
2228:
2225:
2223:
2220:
2218:
2215:
2214:
2212:
2208:
2204:
2200:
2197:
2193:
2186:
2181:
2179:
2174:
2172:
2167:
2166:
2163:
2150:
2146:
2145:
2141:
2140:
2137:
2133:
2126:
2122:
2121:
2117:
2115:
2111:
2110:
2106:
2103:
2102:
2098:
2094:
2093:
2090:
2085:
2081:
2074:
2065:
2061:
2056:
2051:
2047:
2043:
2039:
2035:
2031:
2024:
2021:
2016:
2012:
2008:
2004:
2000:
1996:
1992:
1988:
1981:
1978:
1973:
1969:
1964:
1959:
1955:
1951:
1947:
1943:
1939:
1932:
1929:
1924:
1920:
1916:
1912:
1908:
1904:
1896:
1893:
1888:
1884:
1880:
1876:
1872:
1868:
1864:
1860:
1853:
1850:
1845:
1839:
1836:
1831:
1825:
1822:
1817:
1813:
1809:
1805:
1801:
1797:
1793:
1789:
1782:
1779:
1774:
1770:
1765:
1760:
1755:
1750:
1746:
1742:
1741:F1000Research
1738:
1731:
1728:
1723:
1719:
1714:
1709:
1705:
1701:
1697:
1693:
1689:
1682:
1680:
1676:
1671:
1667:
1662:
1657:
1653:
1649:
1645:
1641:
1637:
1630:
1627:
1622:
1618:
1614:
1610:
1605:
1600:
1596:
1592:
1588:
1584:
1576:
1573:
1568:
1564:
1560:
1556:
1551:
1546:
1542:
1538:
1534:
1530:
1526:
1519:
1516:
1511:
1507:
1502:
1497:
1493:
1489:
1485:
1481:
1477:
1470:
1467:
1462:
1458:
1454:
1450:
1446:
1442:
1439:(1): e28576.
1438:
1434:
1426:
1424:
1420:
1415:
1411:
1407:
1403:
1399:
1395:
1391:
1387:
1380:
1378:
1376:
1374:
1370:
1365:
1361:
1356:
1351:
1347:
1343:
1339:
1332:
1330:
1328:
1326:
1324:
1322:
1320:
1318:
1316:
1314:
1312:
1308:
1303:
1299:
1294:
1289:
1285:
1281:
1277:
1273:
1269:
1262:
1260:
1258:
1256:
1252:
1247:
1243:
1239:
1235:
1231:
1227:
1223:
1219:
1211:
1209:
1207:
1205:
1203:
1201:
1199:
1195:
1190:
1186:
1181:
1176:
1172:
1168:
1164:
1160:
1156:
1148:
1146:
1144:
1142:
1140:
1138:
1136:
1134:
1132:
1130:
1128:
1126:
1122:
1117:
1113:
1109:
1105:
1101:
1097:
1094:(3): e29403.
1093:
1089:
1085:
1078:
1076:
1074:
1072:
1068:
1063:
1059:
1054:
1049:
1044:
1039:
1035:
1031:
1027:
1020:
1018:
1016:
1014:
1012:
1010:
1008:
1006:
1004:
1002:
1000:
998:
996:
994:
992:
988:
983:
979:
975:
971:
966:
961:
957:
953:
952:
947:
940:
937:
932:
926:
922:
915:
913:
909:
904:
900:
896:
892:
888:
884:
881:(2): e28769.
880:
876:
869:
867:
865:
863:
861:
859:
857:
855:
853:
851:
849:
847:
845:
843:
841:
837:
830:
826:
823:
821:
818:
816:
813:
812:
808:
806:
804:
800:
796:
792:
787:
783:
779:
774:
772:
768:
764:
760:
756:
752:
751:actinomycin D
748:
744:
740:
736:
732:
728:
724:
715:
713:
710:
701:
699:
696:
691:
683:
681:
674:
672:
670:
666:
662:
658:
654:
650:
646:
642:
638:
630:
628:
626:
622:
617:
613:
609:
605:
601:
600:STAT proteins
597:
593:
589:
585:
577:
574:
572:
570:
566:
562:
558:
554:
549:
541:
539:
537:
533:
529:
528:chromosome 19
525:
521:
517:
513:
509:
505:
501:
497:
493:
489:
485:
481:
477:
473:
469:
465:
461:
453:
448:
446:
444:
440:
436:
432:
428:
427:smooth muscle
423:
415:
413:
410:
407:
403:
399:
395:
386:
384:
377:
375:
373:
369:
365:
361:
357:
356:temporal bone
353:
349:
345:
341:
340:ethmoid sinus
333:
331:
329:
325:
321:
317:
313:
308:
303:
301:
297:
293:
289:
285:
281:
277:
272:
270:
266:
261:
257:
253:
249:
245:
236:
234:
232:
228:
224:
218:
216:
212:
208:
204:
203:non-malignant
200:
196:
192:
189:
188:
183:
182:
177:
172:
169:
165:
161:
157:
152:
150:
149:
144:
140:
136:
132:
128:
124:
120:
116:
107:
103:
99:
97:
93:
89:
88:
83:
79:
75:
71:
67:
63:
60:
56:
53:
51:
47:
43:
39:
34:
19:
2823:Mesothelioma
2780:Wilms' tumor
2467:Fibroadenoma
2369:Histiocytoma
2286:fibromatosis
2259:fibrosarcoma
2227:Skin sarcoma
2142:
2118:
2107:
2095:
2040:(2): 70–84.
2037:
2033:
2023:
1990:
1986:
1980:
1945:
1941:
1931:
1909:(1): 47–50.
1906:
1902:
1895:
1862:
1858:
1852:
1838:
1824:
1794:(8): 432–7.
1791:
1787:
1781:
1744:
1740:
1730:
1695:
1691:
1643:
1639:
1629:
1604:11343/275870
1586:
1582:
1575:
1532:
1528:
1518:
1483:
1479:
1469:
1436:
1432:
1389:
1385:
1345:
1341:
1278:(1): e3261.
1275:
1271:
1221:
1217:
1162:
1158:
1091:
1087:
1033:
1029:
958:(1): 39–44.
955:
949:
939:
920:
878:
874:
802:
798:
794:
790:
785:
777:
775:
747:prednisolone
739:methotrexate
731:dactinomycin
723:chemotherapy
719:
705:
687:
678:
657:Beta-catenin
644:
634:
583:
581:
575:
547:
545:
535:
531:
523:
479:
476:chromosome 5
463:
459:
457:
454:Familial IMF
420:Microscopic
419:
390:
381:
337:
327:
323:
319:
315:
311:
306:
304:
299:
290:manner with
279:
273:
256:pedunculated
240:
237:Presentation
230:
223:chemotherapy
219:
198:
194:
185:
179:
173:
167:
159:
155:
153:
148:fibromatosis
146:
121:) is a rare
118:
114:
113:
85:
2815:Mesothelial
2653:Rhabdomyoma
2527:Myelolipoma
2522:liposarcoma
2439:Angiomyxoma
2422:myxosarcoma
2246:Fibromatous
2196:soft tissue
2034:Pathologica
1993:(1): 1–13.
815:Skin lesion
735:vinblastine
727:vincristine
590:stimulates
462:genes. The
352:hard palate
265:spectrogram
211:fibroblasts
151:– in 1954.
135:metastasize
65:Usual onset
55:Neonatology
41:Other names
2843:Categories
2760:Adenomyoma
2609:myosarcoma
2510:Lipomatous
2410:Myxomatous
2192:Connective
831:References
755:prednisone
569:tryptophan
561:asparagine
496:N-terminus
486:Arg, i.e.
484:amino acid
470:32 on the
445:proteins.
404:, rectum,
402:cerebellum
350:, tongue,
59:Pediatrics
2691:Cutaneous
2686:Leiomyoma
2629:Leiomyoma
2588:Myomatous
2578:Hibernoma
1903:Pathology
1621:219331223
1567:231612187
1461:221540155
1414:208275551
1246:204966175
1116:238636902
974:0886-4470
903:222826034
782:sorafenib
653:cyclin D1
631:Diagnosis
625:ponatinib
621:dasatinib
553:aspartate
520:threonine
516:glutamate
416:Pathology
176:mutations
105:Frequency
96:Prognosis
50:Specialty
2482:Synovial
2203:sarcomas
2144:Orphanet
2064:33179614
2015:30315278
2007:18830128
1972:25295083
1923:27020209
1887:49410224
1879:29943820
1816:32983693
1808:25989870
1773:30613391
1747:: 1963.
1722:33509954
1670:31645346
1613:32500973
1559:33449152
1550:11072557
1510:28248815
1453:32896962
1406:31764512
1364:28334876
1302:33552804
1238:31670833
1189:32888134
1108:34636137
1062:34449594
895:33063933
809:See also
763:cytokine
616:imatinib
546:Somatic
488:arginine
439:calponin
406:parietal
368:pancreas
276:germline
260:necrotic
2597:General
2282:Fibroma
2255:Fibroma
2125:D018224
2104:: D48.1
2055:8167394
1963:4186628
1764:6305242
1713:7927659
1661:6824247
1501:5391281
1293:7858576
1180:8484085
1053:8395860
982:9932585
641:nodular
637:papular
606:γ, and
504:leucine
500:proline
492:cystine
360:scapula
267:and/or
252:plaques
248:nodules
244:papules
225:drugs,
2539:PEComa
2518:Lipoma
2418:Myxoma
2199:tumors
2114:228550
2062:
2052:
2013:
2005:
1970:
1960:
1921:
1885:
1877:
1814:
1806:
1771:
1761:
1720:
1710:
1668:
1658:
1619:
1611:
1565:
1557:
1547:
1508:
1498:
1459:
1451:
1412:
1404:
1362:
1300:
1290:
1244:
1236:
1187:
1177:
1114:
1106:
1060:
1050:
980:
972:
927:
901:
893:
799:PDGFRB
791:PDGFRB
778:PDGFRB
645:PDGFRB
584:PDGFRB
576:PDGFRB
565:lysine
563:, Lys=
557:valine
555:, Val=
548:PDGFRB
536:NOTCH3
532:PDGFRB
524:NOTCH3
514:, Glu=
512:lysine
508:serine
502:, Leu=
480:PDGFRB
464:PDGFRB
460:PDGFRB
443:desmin
409:cortex
372:spleen
364:axilla
328:NOTCH3
324:PDGFRB
320:NOTCH3
316:PDGFRB
312:NOTCH3
307:NOTCH3
300:PDGFRB
280:PDGFRB
231:PDGFRB
199:PDGFRB
195:PDGFRB
187:NOTCH3
181:PDGFRB
139:organs
131:benign
87:PDGFRB
81:Causes
2738:STUMP
2605:Myoma
2484:-like
2011:S2CID
1883:S2CID
1812:S2CID
1698:(2).
1617:S2CID
1563:S2CID
1457:S2CID
1410:S2CID
1242:S2CID
1112:S2CID
899:S2CID
737:plus
729:plus
123:tumor
73:Types
2201:and
2149:2591
2120:MeSH
2109:OMIM
2060:PMID
2003:PMID
1968:PMID
1919:PMID
1875:PMID
1804:PMID
1769:PMID
1718:PMID
1666:PMID
1609:PMID
1555:PMID
1506:PMID
1449:PMID
1402:PMID
1360:PMID
1298:PMID
1234:PMID
1185:PMID
1104:PMID
1058:PMID
978:PMID
970:ISSN
925:ISBN
891:PMID
761:. A
655:and
623:and
608:GRB2
582:The
578:gene
468:band
396:and
191:gene
108:rare
90:gene
2097:ICD
2050:PMC
2042:doi
2038:113
1995:doi
1958:PMC
1950:doi
1911:doi
1867:doi
1863:233
1796:doi
1759:PMC
1749:doi
1708:PMC
1700:doi
1656:PMC
1648:doi
1599:hdl
1591:doi
1587:182
1545:PMC
1537:doi
1496:PMC
1488:doi
1441:doi
1394:doi
1350:doi
1288:PMC
1280:doi
1226:doi
1175:PMC
1167:doi
1096:doi
1048:PMC
1038:doi
960:doi
956:125
883:doi
474:of
246:or
184:or
119:IMF
2845::
2659::
2147::
2123::
2112::
2101:10
2058:.
2048:.
2036:.
2032:.
2009:.
2001:.
1991:33
1989:.
1966:.
1956:.
1944:.
1940:.
1917:.
1907:48
1905:.
1881:.
1873:.
1861:.
1810:.
1802:.
1792:65
1790:.
1767:.
1757:.
1743:.
1739:.
1716:.
1706:.
1696:14
1694:.
1690:.
1678:^
1664:.
1654:.
1642:.
1638:.
1615:.
1607:.
1597:.
1585:.
1561:.
1553:.
1543:.
1533:78
1531:.
1527:.
1504:.
1494:.
1484:41
1482:.
1478:.
1455:.
1447:.
1437:68
1435:.
1422:^
1408:.
1400:.
1390:42
1388:.
1372:^
1358:.
1346:26
1344:.
1340:.
1310:^
1296:.
1286:.
1274:.
1270:.
1254:^
1240:.
1232:.
1222:74
1220:.
1197:^
1183:.
1173:.
1163:20
1161:.
1157:.
1124:^
1110:.
1102:.
1092:69
1090:.
1086:.
1070:^
1056:.
1046:.
1032:.
1028:.
990:^
976:.
968:.
954:.
948:.
911:^
897:.
889:.
879:68
877:.
839:^
803:3)
795:2)
786:1)
765:,
745:,
733:;
639:,
602:,
598:,
437:,
370:,
346:,
250:;
217:.
205:)
168:3)
160:2)
156:1)
57:,
2655:/
2631:/
2607:/
2520:/
2420:/
2371:/
2284:/
2257:/
2194:/
2184:e
2177:t
2170:v
2099:-
2089:D
2066:.
2044::
2017:.
1997::
1974:.
1952::
1946:8
1925:.
1913::
1889:.
1869::
1846:.
1832:.
1818:.
1798::
1775:.
1751::
1745:7
1724:.
1702::
1672:.
1650::
1644:5
1623:.
1601::
1593::
1569:.
1539::
1512:.
1490::
1463:.
1443::
1416:.
1396::
1366:.
1352::
1304:.
1282::
1276:9
1248:.
1228::
1191:.
1169::
1118:.
1098::
1064:.
1040::
1034:8
984:.
962::
933:.
905:.
885::
362:/
342:/
117:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.